Orthopediatrics (NASDAQ:KIDS) Upgraded to Hold by BidaskClub

BidaskClub upgraded shares of Orthopediatrics (NASDAQ:KIDS) from a sell rating to a hold rating in a research report report published on Friday morning, BidAskClub reports.

A number of other equities research analysts also recently weighed in on KIDS. Zacks Investment Research downgraded Orthopediatrics from a hold rating to a strong sell rating in a report on Tuesday, May 14th. Needham & Company LLC started coverage on Orthopediatrics in a report on Wednesday, June 19th. They set a buy rating and a $53.00 target price for the company. ValuEngine downgraded Orthopediatrics from a buy rating to a hold rating in a report on Thursday. Finally, BTIG Research reissued a buy rating and set a $44.00 target price on shares of Orthopediatrics in a report on Friday, May 10th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. The company presently has an average rating of Hold and an average price target of $46.75.

Shares of KIDS traded down $1.66 during midday trading on Friday, reaching $34.76. 55,541 shares of the stock were exchanged, compared to its average volume of 98,233. Orthopediatrics has a twelve month low of $25.11 and a twelve month high of $47.82. The company has a current ratio of 8.60, a quick ratio of 6.01 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $534.57 million, a P/E ratio of -36.21 and a beta of 0.12. The firm has a 50 day moving average of $37.42.

Orthopediatrics (NASDAQ:KIDS) last posted its earnings results on Wednesday, May 8th. The company reported ($0.21) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.04). Orthopediatrics had a negative return on equity of 16.43% and a negative net margin of 16.71%. The firm had revenue of $14.66 million for the quarter, compared to analyst estimates of $14.67 million. Research analysts expect that Orthopediatrics will post -0.45 EPS for the current year.

A number of hedge funds have recently bought and sold shares of the stock. BlackRock Inc. raised its stake in Orthopediatrics by 12.4% in the fourth quarter. BlackRock Inc. now owns 455,657 shares of the company’s stock valued at $15,894,000 after purchasing an additional 50,179 shares in the last quarter. Northern Trust Corp raised its stake in Orthopediatrics by 30.8% in the fourth quarter. Northern Trust Corp now owns 135,143 shares of the company’s stock valued at $4,713,000 after purchasing an additional 31,787 shares in the last quarter. American Century Companies Inc. acquired a new position in Orthopediatrics in the fourth quarter valued at about $3,880,000. Roubaix Capital LLC acquired a new position in Orthopediatrics in the second quarter valued at about $3,497,000. Finally, Geode Capital Management LLC raised its stake in Orthopediatrics by 51.9% in the fourth quarter. Geode Capital Management LLC now owns 80,310 shares of the company’s stock valued at $2,801,000 after purchasing an additional 27,429 shares in the last quarter. 48.56% of the stock is owned by institutional investors and hedge funds.

About Orthopediatrics

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, RESPONSE Spine systems, Bandloc, and Pediguard.

See Also: Day Trading

Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.